Skip to main content

Table 2 Summary of plasma metformin, remogliflozin etabonate, remogliflozin, and GSK279782 PK parameters

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Metformin PK parameter

MET BID

MET + RE BID

N = 13

N = 13

AUC(0–12) (h.ng/mL)

7141.3 (24)

7520.8 (27)

Cmax (ng/mL)

1018.2 (26)

1025.3 (25)

tmax (h)

4.0 (1.0 - 6.0)

4.0 (1.0–6.0)

Remogliflozin etabonate (prodrug) PK Parameter

RE BID

MET + RE BID

N = 12-13 a

N = 12-13 a

AUC(0–last) (h.ng/mL)

98.9 (69)

102.1 (49)

Cmax (ng/mL)

79.5 (107)

67.7 (77)

tmax (h)

3.0 (1.0–4.0)

3.0 (1.0–6.0)

Remogliflozin (active entity) PK Parameter

RE BID

MET + RE BID

N = 13

N = 13

AUC(0–12) (h.ng/mL)

6814.3 (33)

6425.9 (33)

Cmax (ng/mL)

2688.6 (52)

2124.6 (63)

tmax (h)

3.0 (1.0–4.0)

3.0 (1.0 - 6.0)

GSK279782 (active metabolite) PK Parameter

RE BID

MET + RE BID

N = 13

N = 13

AUC(0–12) (h.ng/mL)

1527.9 (37)

1472.9 (36)

Cmax (ng/mL)

462.8 (39)

361.9 (38)

tmax (h)

4.0 (1.0–4.0)

4.0 (1.0–8.0)

  1. Values are geometric mean (%CVb) for each parameter, except for tmax which is median (range). PK, pharmacokinetic; MET BID, metformin 500 mg every 12 hours; MET + RE BID, metformin 500 mg + remogliflozin etabonate 500 mg every 12 hours; RE BID, remogliflozin etabonate 500 mg every 12 hours.
  2. a AUC not evaluable for one subject.
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us